## **HEALTHY U** CHIP

## PRIOR AUTHORIZATION REQUEST FORM Neuromyelitis Optica Spectrum Disorder (NMOSD)

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior

Authorization Department at 801-213-1547. Failure to submit clinical documentation to support this request will result in a dismissal of the request. If you have medical pharmacy prior authorization questions, please call for assistance: 833-981-0212 Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements. Date: Member Name: ID#: DOB: Gender: Physician: Office Phone: Office Fax: Office Contact: Height/Weight: **HCPCS Code:** Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested: ☐ Enspryng ® (satralizumab), ☐ Ruxience ® (rituximab-pvvr), ☐ Soliris® (eculizumb), ☐ Uplizna™ (inebilizumab-cdon) Dosing/Frequency:\_\_ If the request is for reauthorization, proceed to reauthorization section. Questions Yes No **Comments/Notes** 1. Is the request made by, or in consultation with, a specialist in the treatment of neuromyelitis optica spectrum disorder (NMOSD)? 2. Does the member have a confirmed diagnosis of NMOSD with Please provide documentation positive AQP-4 antibodies and at least one core clinical characteristic such as: optic neuritis, acute myelitis, area postrema syndrome, acute brainstem syndrome, symptomatic narcolepsy, acute diencephalic clinical syndrome, or symptomatic cerebral syndrome with brain lesions? 3. Is an Expanded Disability Status Scare (EDSS) score equal to 8 or П П Please provide documentation 4. Has the member had at least 1 relapse that required rescue Please provide documentation therapy in the last 12 months or 2 or more relapses that required rescue therapy in the last 24 months? 5. Has the member had an adequate trial and failure of any of the Please provide documentation П П medications listed in this policy? **REAUTHORIZATION** 1. Is the request for reauthorization of therapy? 2. Does documentation show a clinically significant response to Please provide documentation therapy demonstrated by one of the following: • Decrease in relapse rate

<ul> <li>Improvement of symptoms or stabilization of symptoms</li> </ul>			
associated with relapse			
Improvement in EDSS score			
What medications and/or treatment modalities have been tried in the past for this condition? Please document			
name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\*

Policy: PHARM-CHIP-M027 Origination Date: 07/01/2024 Reviewed/Revised Date: Next Review Date:

Current Effective Date: 07/01/2024

## **Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.